-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O2.6 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma

Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, clinical trials, adult, Clinical Practice (Health Services and Quality), Non-Biological therapies, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, drug development, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Sunday, December 11, 2022: 12:00 PM-1:30 PM
New Orleans Theater C (Ernest N. Morial Convention Center)
Pieter Sonneveld, MD, Erasmus MC and Katja C. Weisel, MD, University Medical Center Hamburg-Eppendorf
Weisel: Amgen: Consultancy, Honoraria, Research Funding; BMS/Celgene: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Adaptive Biotech: Consultancy, Honoraria; AstraZeneca: Honoraria; BeiGene: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Stemline: Honoraria; Pfizer: Honoraria.
Selected new drugs; focus on efficacy and safety data. Also focus on novel clinical approaches and important clinical strategies.
12:00 PM

Dan T. Vogl, MD1, Shebli Atrash, MD2*, Sarah A. Holstein, MD, PhD3, Omar Nadeem, MD4, Don M. Benson Jr., MD5, Kaveri Suryanarayan, MD6*, Yuyin Liu6*, Sabrina Collins6*, Xavier Parot, MD6* and Jonathan L. Kaufman, MD7

1Abramson Cancer Center, Trustees of The University of Pennsylvania, Philadelphia, PA
2Levine Cancer Institute, Charlotte, NC
3University of Nebraska Medical Center, Omaha, NE
4Dana-Farber Cancer Institute, Boston, MA
5Ohio State University Comprehensive Cancer Center, Columbus, OH
6Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

12:15 PM

Luciano J. Megala Costa, MD, PhD1, Shaji K Kumar, MD2, Shebli Atrash, MD3*, Michaela Liedtke, MD4, Gurbakhash Kaur, MD5, Benjamin A. Derman, MD6, P. Leif Bergsagel, MD7, Sham Mailankody, MBBS 8, Philip L. McCarthy, MD9, Josiana Limones10*, Yanping Chen, PhD10*, Sharmila Das10*, Jerill Thorpe, BS10*, Jonathan Cacciatore10*, Garnet Navarro10*, Ashley K Koegel10*, Michael R. Burgess, MD, PhD10*, Kristen Hege, MD10 and Shambavi Richard, MD11

1University of Alabama at Birmingham Hospital, Vestavia, AL
2Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
3Atrium Health Levine Cancer Institute, Charlotte, NC
4Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
5Division of Hematologic Malignancies and Cellular Therapy, Dept of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
6Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
7Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
8Memorial Sloan Kettering Cancer Center, New York, NY
9Roswell Park Comprehensive Cancer Center, Buffalo, NY
10Bristol Myers Squibb, Princeton, NJ
11Mount Sinai Health System, New York, NY

12:30 PM

Suzanne Trudel1, Nizar J. Bahlis, MD2, Andrew Spencer3, Rayan Kaedbey, MD4, Paula Rodriguez Otero5*, Simon J Harrison, MD6, Chihunt Wong7*, Grant R. Goodman, MD7, Rin Nakamura7*, Voleak Choeurng7*, James Cooper7* and Maria-Victoria Mateos, MD8

1Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
2Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
3Alfred Health-Monash University, Melbourne, VIC, Australia
4Jewish General Hospital, McGill University, Montreal, QC, Canada
5Clínica Universidad de Navarra, Pamplona, Spain
6Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia
7Genentech, Inc., South San Francisco, CA
8Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain

12:45 PM

Paul G. Richardson, MD1, Suzanne Trudel2, Hang Quach3, Rakesh Popat4*, Sagar Lonial, MD5, Robert Z. Orlowski, MD, PhD6, Kihyun Kim, MD7, María-Victoria Mateos, MD, PhD8, Charlotte Pawlyn, PhD9,10, Karthik Ramasamy11, Joaquín Martinez-Lopez, MD, PhD12*, Alessia Spirli13*, Ignacio Casas-Avilés, MD14*, Jing Gong, PhD15*, Michael Amatangelo, PhD15*, Jessica Katz, MD PhD15*, Paulo Maciag, MD PhD15*, Teresa Peluso13* and Nizar J. Bahlis, MD16

1Dana-Farber Cancer Institute, Boston, MA
2Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
3St. Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia
4NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
5Winship Cancer Institute, Emory University, Atlanta, GA
6Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
7Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan Univ. Sch. of Med. Samsung Medical Center, Seoul, Korea, Republic of (South)
8University Hospital of Salamanca/IBSAL, Salamanca, Spain
9The Royal Marsden NHS Foundation, London, United Kingdom
10The Institute of Cancer Research, London, United Kingdom
11Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
12Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain
13Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
14Hospital San Pedro de Alcántara, Cáceres, Spain
15Bristol Myers Squibb, Princeton, NJ
16University of Calgary, Calgary, AB, Canada

1:00 PM

Salomon Manier, MD, PhD1, Jill Corre2*, Cyrille Hulin3*, Kamel Laribi4*, Carla Araujo5*, Gian-Matteo Pica, MD6*, Cyrille Touzeau7*, Pascal Godmer, MD8*, Bohrane Slama9*, Lionel Karlin10*, Frederique Orsini-Piocelle11*, Mamoun Dib, MD12*, Margaret Macro, MD13*, Laurence Sanhes, MD14*, Aurore Perrot, MD, PhD15*, Jean Yves Mary, PhD16*, Jerome Lambert, MD, PhD17*, Herve Avet-Loiseau, MD, PhD18*, Philippe Moreau, MD19*, Xavier Leleu, MD, PhD20 and Thierry Facon21*

1Lille University Hospital, Lille, France
2Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
3Department of Hematology, University Hospital Bordeaux, Bordeaux, France
4Le Mans University Hospital, Le Mans, FRA
5Centre Hospitalier de la Cote Basque, Bayonne, France, Bayonne, FRA
6Department of Hematology, Centre Hospitalier Métropole Savoie Chambéry, Chambéry, France
7University Hospital Hôtel Dieu, Nantes Cedex 1, FRA
8Clinical Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France
9CH Avignon, Avignon, FRA
10Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Bénite, France
11Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, FRA
12Hématologie - CHU - Hôpital du Bocage, Angers, France
13Haematology Department, Caen University Hospital, Caen, France
14Department of Hematology, CH de Perpignan, Perpignan, France
15Department of Hematology, Toulouse University Institute of Cancer, Toulouse, France
16INSERM, Paris, France
17Biostatistics Department, University of Paris, AP-HP, Saint Louis Hospital, Paris, FRA
18Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
19Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
20Department of Oncology-Haematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France
21Department of Hematology, Lille University Hospital, Lille, France

1:15 PM

Charlotte Pawlyn, PhD1,2, Tom Menzies3*, Faith E Davies, MD4, Ruth M. de Tute5*, Rowena Henderson3*, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath3,6*, Matthew W Jenner7*, John R Jones, MD8,9,10*, Martin F. Kaiser, MD, FRCP, FRCPath1,2, Mark T Drayson, MD11*, Roger G Owen5*, David Cairns, PhD3*, Gareth J. Morgan, MD4 and Graham Jackson, MBBS, FRCP, FRCPath, MA, DM12

1The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
2The Institute of Cancer Research, London, United Kingdom
3Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
4Perlmutter Cancer Center, NYU Langone Health, New York, NY
5HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
6Leeds Cancer Centre, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
7Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
8Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom
9King's College Hospital NHS Foundation Trust, London, United Kingdom
10Eastbourne District General Hospital, Eastbourne, United Kingdom
11Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
12Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom

*signifies non-member of ASH